Eosinophilic Esophagitis: Food Triggers, Elimination Diets & the Case for Dupilumab

The Biology: Why the Esophagus Fills With Eosinophils

Eosinophilic esophagitis is not acid reflux. It is not an infection. It is a Th2-mediated chronic inflammatory disease driven by food antigens and, to a lesser extent, aeroallergens — most prominently in spring and autumn, which correlate with flares in a subset of patients.

Under normal circumstances, the esophagus contains virtually zero eosinophils. In EoE, the immune system misidentifies dietary proteins as threats. The result is a cytokine cascade centered on three key molecules:

• IL-5 — promotes eosinophil production in bone marrow and prolongs their survival in esophageal tissue
• IL-13 — directly induces epithelial barrier dysfunction, promotes subepithelial fibrosis, and drives eotaxin-3 secretion from esophageal epithelial cells
• Eotaxin-3 (CCL26) — a chemokine secreted by esophageal epithelial cells that acts as a homing signal, recruiting blood eosinophils into the mucosa

This combination creates a self-amplifying loop: damaged epithelium releases more eotaxin-3, which recruits more eosinophils, which release toxic granule proteins — major basic protein, eosinophil peroxidase — that further injure the epithelium. Over years, uncontrolled inflammation drives subepithelial fibrosis, leading to the classic EoE complications: esophageal rings (trachealization), furrows, strictures, and narrow-caliber esophagus.

EREFS: Scoring Endoscopic Disease Activity

The EoE Endoscopic Reference Score (EREFS) quantifies five endoscopic features: Edema, Rings, Exudates, Furrows, and Stricture. Each feature is graded 0–3 (rings/stricture) or 0–2 (others). Total EREFS correlates moderately with histologic eosinophil counts but is imperfect — some patients with severe histologic disease have near-normal endoscopic appearance, underscoring the importance of biopsies even in visually unremarkable esophagi. Serial EREFS tracking provides useful longitudinal data on structural disease progression.

The Top 6 Food Triggers: What Elimination Studies Show

EoE is not an IgE-mediated food allergy in the traditional sense. Standard skin-prick testing and serum IgE panels perform poorly at identifying EoE triggers. The only reliable method remains dietary elimination followed by structured reintroduction with repeat endoscopy and biopsy at each food group reintroduction.

Six food groups account for the vast majority of EoE triggers identified through systematic reintroduction studies:

Trigger rates are not additive — a patient may be sensitive to one group or several. The critical principle is that allergy testing cannot substitute for dietary elimination. IgE-guided elimination performs no better than standard six-food elimination and often leads to unnecessary restrictions or missed triggers.

Elimination Diet Strategies: 2022 Guideline Step-Up Hierarchy

The 2022 AGA/JTF guidelines represented a significant shift in how elimination diets are sequenced. Rather than defaulting to the most restrictive approach, current guidelines favor a step-up strategy — starting with fewer eliminated foods and escalating only if initial trials fail. This minimizes dietary burden while systematically identifying responders at each level.

1-Food Elimination Diet (1-FED): Milk Only

Eliminating dairy alone achieves histologic remission in approximately 30–40% of adults. Given that cow's milk is the single most prevalent EoE trigger, 2022 guidelines position this as the preferred first-line dietary approach in adults. It minimizes nutritional impact, simplifies compliance, and identifies the most common culprit with a single 6–8 week trial. If repeat biopsy shows persistent eosinophilia, escalate to the 2-food approach.

2-Food Elimination Diet (2-FED): Milk + Wheat

Adding wheat elimination to dairy removal produces remission in approximately 40–60% of patients. This combination targets the two highest-yield triggers and represents the pragmatic midpoint between simplicity and efficacy. Most adults can manage this restriction without significant nutritional compromise when guided by a dietitian familiar with EoE.

4-Food Elimination Diet (4-FED): Milk, Wheat, Egg, Soy

Removing the top four food groups achieves remission in approximately 54–64% of patients — a meaningful gain over 2-FED for non-responders. The 4-FED is more nutritionally demanding. Soy elimination is particularly challenging given its ubiquity in processed foods as a hidden ingredient. Egg removal reduces protein options significantly. Dietitian involvement is strongly recommended at this level.

6-Food Elimination Diet (6-FED / SFED): The Ceiling of Dietary Efficacy

The six-food elimination diet removing milk, wheat, egg, soy, nuts, and seafood achieves histologic remission in 70–80% of patients — the highest remission rate of any dietary intervention. The real-world challenge is the reintroduction phase: each food group requires a separate 6-week elimination, endoscopy, and biopsy cycle. Completing full reintroduction to identify a patient's specific triggers can take 18–24 months and multiple endoscopies. For many adults, this burden drives preference for pharmacological approaches instead.

Reintroduction Protocol

During 6-FED reintroduction, food groups are typically added back in order of least-likely to most-likely trigger: seafood → nuts → soy → egg → wheat → dairy. Each reintroduction lasts 6–8 weeks, followed by endoscopy with biopsies from both proximal and distal esophagus. A threshold of ≥15 eos/hpf confirms that food as a trigger, and it is re-eliminated while the next food group reintroduction proceeds in parallel.

Pharmacological Treatments: From PPIs to Biologics

Proton Pump Inhibitor (PPI) Trial

Despite EoE being primarily an immune rather than acid-driven disease, PPIs achieve histologic remission in approximately 50% of patients. The mechanism is not solely acid suppression — PPIs appear to directly inhibit IL-4 and IL-13-induced eotaxin-3 secretion by esophageal epithelial cells, reducing eosinophil recruitment independently of pH changes. Standard dosing uses twice-daily high-dose PPI (e.g., omeprazole 40mg BID or equivalent) for 8 weeks before diagnostic endoscopy. PPI responders still have EoE biologically; recurrence on discontinuation is common, and maintenance is typically required.

Swallowed Topical Corticosteroids

For patients who fail PPI monotherapy, swallowed topical corticosteroids deliver anti-inflammatory medication directly to the esophageal mucosa with minimal systemic absorption. Two agents dominate clinical use:

• Fluticasone propionate — MDI inhaler swallowed (not inhaled); 440–880mcg/day in divided doses. The patient swallows the puff without a spacer, then avoids eating or drinking for 30 minutes to maximize mucosal contact. Histologic remission rates of 50–70% in clinical trials.
• Budesonide oral viscous suspension (OVS) — specifically formulated for esophageal coating; superior mucosal contact time versus inhaler technique. FDA-approved as Eohilia in 2024 for adolescents and adults with EoE. Remission rates 53–72% at 12 weeks in pivotal trials.

The primary concern with long-term topical steroids is esophageal candidiasis (estimated 5–15% incidence), requiring periodic monitoring. Systemic absorption is low but non-zero; adrenal suppression is rare at standard doses but warrants consideration in pediatric patients or long-term adult users.

Dupilumab (Dupixent): The First FDA-Approved Biologic for EoE

In May 2022, the FDA approved dupilumab for eosinophilic esophagitis in adults and adolescents ≥12 years weighing ≥40kg — the first biologic therapy approved for this condition. Dupilumab is a fully human monoclonal antibody targeting the IL-4 receptor alpha (IL-4Rα) subunit, which is shared by the IL-4 and IL-13 signaling pathways. By blocking this single receptor subunit, dupilumab simultaneously inhibits both IL-4 and IL-13 — the two primary cytokines driving EoE pathology upstream.

The pivotal Part A data from LIBERTY-EoE-TREET demonstrated:

• Histologic remission (≤6 eos/hpf) achieved in 60% of dupilumab-treated patients vs 5% placebo at week 24
• Significant reduction in Dysphagia Symptom Questionnaire (DSQ) scores
• Meaningful improvement in EREFS endoscopic scores
• Favorable safety profile consistent with atopic disease trials (injection site reactions ~10%, conjunctivitis ~10%)

Dupilumab is administered as 300mg subcutaneous injection every 2 weeks. Because it targets upstream Th2 signaling, it addresses the root immune mechanism rather than just suppressing inflammation — making it particularly attractive for patients with concurrent atopic conditions (atopic dermatitis, asthma, allergic rhinitis) who may already receive dupilumab for those indications.

Esophageal Dilation: Managing Fibrotic Complications

Dilation does not treat the underlying inflammation — it is a mechanical intervention for fibrotic strictures and rings that physically impair swallowing. Endoscopic dilation (bougie or through-the-scope balloon) is indicated when luminal narrowing persists despite achieving histologic remission, or when food impaction risk is clinically significant. The procedure carries a small but real risk of esophageal perforation (estimated 0.1–0.3%) and expected mucosal tears that are generally self-limited. Post-dilation, anti-inflammatory treatment must continue to prevent fibrotic recurrence.

Chronic Disease Management: Why Maintenance Is Non-Negotiable

EoE follows a chronic-relapsing course in the vast majority of patients. Unlike peptic ulcer disease cured by H. pylori eradication, EoE has no definitive cure — the underlying immune predisposition persists. Discontinuing effective treatment, whether dietary or pharmacological, results in histologic relapse in 80–90% of patients within 3–6 months.

The clinical implication is straightforward: whichever treatment achieves remission must be maintained indefinitely, or until a deliberate shared decision to transition strategies. This is especially important given EoE's natural history — progressive subepithelial fibrosis leads to esophageal remodeling, stricture formation, and ultimately a rigid narrow-caliber esophagus that is mechanically impaired regardless of inflammatory control at that stage.

Monitoring During Maintenance

No validated non-invasive biomarker for EoE disease activity currently exists. Serum eosinophil counts, IgE levels, and blood inflammatory markers do not reliably reflect esophageal tissue eosinophilia. Monitoring currently requires periodic upper endoscopy with biopsies — typically every 1–2 years in stable disease, or sooner if symptoms change or dietary and medication adjustments are made. Research into esophageal string testing, cytosponge sampling, and salivary biomarkers is ongoing but not yet standard of care.

Nutritional Considerations on Long-Term Elimination Diets

Patients maintaining EoE on long-term dietary restriction require structured nutritional support. Specific risks by eliminated food group include calcium and vitamin D deficiency on dairy-free diets, B vitamins (particularly thiamine and niacin) on wheat-free diets, and protein adequacy on diets restricting multiple sources simultaneously. Periodic assessment by a registered dietitian with GI expertise and targeted supplementation when indicated is standard-of-care for patients on 4-FED or 6-FED maintenance.

Frequently Asked Questions

Can EoE go away on its own without treatment?

No. EoE is a chronic condition that does not spontaneously resolve. Without treatment, ongoing eosinophilic inflammation drives progressive fibrosis and esophageal remodeling. Early intervention — before fibrotic changes become structural — gives the best long-term prognosis for maintaining normal esophageal function and swallowing capacity.

Can children with EoE outgrow it?

Unlike some IgE-mediated food allergies, EoE does not appear to be commonly outgrown. Long-term pediatric follow-up studies show persistent disease into adulthood in the majority of patients. Some children may develop tolerance to specific trigger foods over time during structured dietary reintroduction, but the underlying EoE immune susceptibility generally persists, requiring ongoing monitoring and maintenance therapy through adolescence and into adult gastroenterology care.

How is EoE different from GERD?

GERD is driven by acid reflux from the stomach into the esophagus — fundamentally an anatomical and motility problem. EoE is immune-driven: eosinophils are recruited by Th2 cytokines in response to dietary antigens, not by acid exposure. Symptoms can overlap (heartburn, chest pain, regurgitation) but EoE also presents with dysphagia, food impaction, and requires biopsy for definitive diagnosis. Standard acid suppression partially addresses EoE through eotaxin-3 inhibition but does not fully resolve the underlying immune mechanism in most patients.

Is EoE hereditary?

EoE has significant genetic underpinnings. Twin concordance studies suggest heritability of 40–60%. Key susceptibility loci include the 5q22 region (TSLP gene, which promotes Th2 polarization) and the 2p23 region (CAPN14, encoding calpain-14, which affects esophageal epithelial barrier integrity). First-degree relatives of EoE patients carry approximately 10-fold higher risk of developing EoE compared to the general population, making family history clinically relevant during diagnostic workup.

What should I eat during an EoE flare?

During active EoE with significant dysphagia, soft, moist, well-chewed foods reduce food impaction risk. Approach with caution: dry meats, bread without liquid, raw fibrous vegetables, and pills taken without adequate water. These are symptom-management strategies — dietary elimination of your specific trigger foods (identified through elimination protocol) addresses the underlying cause. Always discuss acute dietary management and safe swallowing strategies with your gastroenterologist and dietitian.

Related on GutCode